Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | PPARD | Q03181 | 10/20 | 0.58 |
| ▸ | PPARA | Q07869 | 9/20 | 0.58 |
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016720 | 0.92 | MAPT (0.57) | MAPTPPARDPPARAPPARGFFAR1 | |
| SCHEMBL1508353 | 0.88 | NPC1 (0.58) | MAPTPPARDPPARAPPARGFFAR1 | |
| SCHEMBL13241455 | 0.87 | MAPT (0.58) | MAPTPPARDPPARAPPARGFFAR1 | |
| SCHEMBL5691166 | 0.86 | MAPT (0.60) | MAPTPPARDPPARAPPARGFFAR1 | |
| SCHEMBL27651049 | 0.86 | MAPT (0.57) | MAPTPPARDPPARAPPARGFFAR1 | |
| SCHEMBL3372790 | 0.84 | ALDH1A1 (0.60) | MAPTPPARDPPARAPPARGNPC1 | |
| SCHEMBL11926060 | 0.84 | NPC1 (0.56) | MAPTPPARDPPARAPPARGFFAR1 | |
| SCHEMBL5015456 | 0.82 | NPC1 (0.54) | MAPTPPARDPPARAPPARGFFAR1 | |
| SCHEMBL977726 | 0.82 | MAPT (0.59) | MAPTPPARDPPARAPPARGFFAR1 | |
| SCHEMBL3822273 | 0.82 | NPC1 (0.58) | MAPTPPARDPPARAPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537091-B1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| CN-1816550-B | Indolyl derivatives substituted with a thiazole ring and their use as PPAR modulators | HOFFMANN LA ROCHE | 2010-04-28 | — | — | CN | disclosed |
| CN-100475810-C | Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-1644368-B1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7235572-B2 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| CN-1816550-A | Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | CN | disclosed |
| EP-1644368-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| EP-1636198-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| CN-1678596-A | Novel 2-arylthiazole compounds as PPAR alpha and PPAR gamma agonists | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | CN | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005005423-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004111020-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | MAPT 4327/4885PPARD 79/4885PPARA 287/4885 |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | MAPT 3099/4885PPARD 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.